There are 807 resources available
162MO - Genomic characterization revealed from prospective clinical sequencing of 1016 Chinese prostate cancer patients
Presenter: Yu Wei
Session: Mini Oral session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast
139MO - Prognostic significance of the mechanism of inflammatory markers in advanced renal cell carcinoma patients treated with nivolumab plus ipilimumab
Presenter: Takayuki Nakayama
Session: Mini Oral session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 162MO and 139MO
Presenter: Nobuaki Matsubara
Session: Mini Oral session: Genitourinary tumours
Resources:
Slides
Webcast
Updates on the strategy of treatment in pancreatic cancer in Asia
Presenter: Teresa Macarulla
Session: Servier - Understanding the treatment landscape in pancreatic cancer
Resources:
Webcast
Opening remarks
Presenter: Ross Soo
Session: Thermofisher Scientific and Janssen Pharmaceuticals - Riding the new waves of success: Latest strategies in the screening and management of NSCLC patients with EGFR exon 20 insertion mutations
Resources:
Webcast
Treatment strategy for metastatic pancreatic ductal adenocarcinoma: Surgeon’s point of view
Presenter: Sohei Satoi
Session: Servier - Understanding the treatment landscape in pancreatic cancer
Resources:
Webcast
Setting out the sail in advanced NSCLC: The role of comprehensive genomic testing in advanced NSCLC
Presenter: Timothy Tay
Session: Thermofisher Scientific and Janssen Pharmaceuticals - Riding the new waves of success: Latest strategies in the screening and management of NSCLC patients with EGFR exon 20 insertion mutations
Resources:
Webcast
Japanese real-world data of Nal-IRI+5-FU/LV and the impact of UGT1A1 polymorphisms on treatment outcomes
Presenter: Kazuaki Harada
Session: Servier - Understanding the treatment landscape in pancreatic cancer
Resources:
Webcast
Watching out for the tsunami: The burden of unmet need in advanced NSCLC patients with EGFR exon 20 insertion mutations
Presenter: Ross Soo
Session: Thermofisher Scientific and Janssen Pharmaceuticals - Riding the new waves of success: Latest strategies in the screening and management of NSCLC patients with EGFR exon 20 insertion mutations
Resources:
Webcast
Role of Nal-IRI in second-line treatment: Japanese oncologist’s perspective
Presenter: Masafumi Ikeda
Session: Servier - Understanding the treatment landscape in pancreatic cancer
Resources:
Webcast